Does the media refer more to FHTX or ORIC?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Oric Pharmaceuticals and 1 mentions for Foghorn Therapeutics. Oric Pharmaceuticals' average media sentiment score of 1.14 beat Foghorn Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MLTX or FHTX?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Foghorn Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.85 beat Foghorn Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, VOR or FHTX?

Vor Biopharma has higher earnings, but lower revenue than Foghorn Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Foghorn Therapeutics $30.91M 13.57 -$74.28M -$0.98 N/A

Is VOR or FHTX more profitable?

Vor Biopharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Foghorn Therapeutics -175.78% N/A -31.17%

Does the media prefer AVBP or FHTX?

In the previous week, ArriVent BioPharma had 11 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 12 mentions for ArriVent BioPharma and 1 mentions for Foghorn Therapeutics. ArriVent BioPharma's average media sentiment score of 0.54 beat Foghorn Therapeutics' score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AKTS or FHTX more profitable?

Aktis Oncology has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Foghorn Therapeutics -175.78% N/A -31.17%

Does the media refer more to AKTS or FHTX?

In the previous week, Aktis Oncology had 8 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 9 mentions for Aktis Oncology and 1 mentions for Foghorn Therapeutics. Aktis Oncology's average media sentiment score of 0.54 beat Foghorn Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Foghorn Therapeutics (FHTX) Competitors

$7.06 +0.20 (+2.84%)

As of 11:24 AM Eastern

Compare

FHTX vs. ORIC, MLTX, VOR, AVBP, and AKTS

Should you buy Foghorn Therapeutics stock or one of its competitors? Foghorn Therapeutics's main competitors and comparable companies include Oric Pharmaceuticals (ORIC), MoonLake Immunotherapeutics (MLTX), Vor Biopharma (VOR), ArriVent BioPharma (AVBP), and Aktis Oncology (AKTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Foghorn Therapeutics compare to Oric Pharmaceuticals?

Foghorn Therapeutics (NASDAQ:FHTX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Oric Pharmaceuticals has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Foghorn Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Foghorn Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	13.57	-$74.28M	-$0.98	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for Oric Pharmaceuticals and 1 mentions for Foghorn Therapeutics. Oric Pharmaceuticals' average media sentiment score of 1.14 beat Foghorn Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Foghorn Therapeutics presently has a consensus price target of $11.43, indicating a potential upside of 61.76%. Oric Pharmaceuticals has a consensus price target of $19.45, indicating a potential upside of 37.95%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Foghorn Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Foghorn Therapeutics beats Oric Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

MoonLake Immunotherapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 2 mentions for MoonLake Immunotherapeutics and 1 mentions for Foghorn Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.85 beat Foghorn Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, indicating a potential upside of 56.21%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 61.76%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Foghorn Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Foghorn Therapeutics	$30.91M	13.57	-$74.28M	-$0.98	N/A

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Summary

Foghorn Therapeutics beats MoonLake Immunotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Vor Biopharma has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, indicating that its stock price is 189% more volatile than the broader market.

Vor Biopharma presently has a consensus price target of $43.38, indicating a potential upside of 82.59%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 61.76%. Given Vor Biopharma's higher possible upside, equities analysts plainly believe Vor Biopharma is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vor Biopharma has higher earnings, but lower revenue than Foghorn Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Foghorn Therapeutics	$30.91M	13.57	-$74.28M	-$0.98	N/A

Vor Biopharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Foghorn Therapeutics	-175.78%	N/A	-31.17%

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Vor Biopharma. MarketBeat recorded 1 mentions for Foghorn Therapeutics and 0 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 0.00 equaled Foghorn Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vor Biopharma	Neutral
Foghorn Therapeutics	Neutral

Summary

Vor Biopharma and Foghorn Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Foghorn Therapeutics compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, ArriVent BioPharma had 11 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 12 mentions for ArriVent BioPharma and 1 mentions for Foghorn Therapeutics. ArriVent BioPharma's average media sentiment score of 0.54 beat Foghorn Therapeutics' score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma currently has a consensus target price of $44.86, suggesting a potential upside of 45.81%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 61.76%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Foghorn Therapeutics has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Foghorn Therapeutics	$30.91M	13.57	-$74.28M	-$0.98	N/A

ArriVent BioPharma has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Foghorn Therapeutics	-175.78%	N/A	-31.17%

ArriVent BioPharma has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

Summary

Foghorn Therapeutics beats ArriVent BioPharma on 12 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Aktis Oncology has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Foghorn Therapeutics	-175.78%	N/A	-31.17%

Aktis Oncology presently has a consensus price target of $35.00, indicating a potential upside of 32.98%. Foghorn Therapeutics has a consensus price target of $11.43, indicating a potential upside of 61.76%. Given Foghorn Therapeutics' higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Aktis Oncology had 8 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 9 mentions for Aktis Oncology and 1 mentions for Foghorn Therapeutics. Aktis Oncology's average media sentiment score of 0.54 beat Foghorn Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aktis Oncology has higher earnings, but lower revenue than Foghorn Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	217.65	-$63.73M	-$0.82	N/A
Foghorn Therapeutics	$30.91M	13.57	-$74.28M	-$0.98	N/A

Summary

Aktis Oncology beats Foghorn Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$419.52M	$4.04B	$7.32B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-7.21	11.84	271.18	24.19
Price / Sales	13.57	1,439.13	697.49	127.82
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	-3.68	17.33	11.25	6.50
Net Income	-$74.28M	-$22.72M	$3.45B	$347.63M
7 Day Performance	4.67%	4.70%	2.90%	1.49%
1 Month Performance	45.67%	12.23%	8.56%	5.12%
1 Year Performance	34.57%	61.19%	27.78%	17.81%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	1.9454 of 5 stars	$7.07 +2.8%	$11.43 +61.8%	+23.6%	$419.52M	$30.91M	N/A	120	Positive News
ORIC Oric Pharmaceuticals	2.4731 of 5 stars	$13.92 +4.0%	$19.45 +39.8%	+38.2%	$1.44B	N/A	N/A	80
MLTX MoonLake Immunotherapeutics	3.0172 of 5 stars	$16.34 -0.1%	$24.57 +50.4%	-72.5%	$1.40B	N/A	N/A	2
VOR Vor Biopharma	2.0286 of 5 stars	$23.28 +1.2%	$43.38 +86.3%	-47.7%	$1.36B	N/A	N/A	140
AVBP ArriVent BioPharma	2.2493 of 5 stars	$30.00 +3.4%	$44.86 +49.5%	+40.5%	$1.35B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. ORIC, MLTX, VOR, AVBP, and AKTS

How does Foghorn Therapeutics compare to Oric Pharmaceuticals?

Summary

How does Foghorn Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Foghorn Therapeutics compare to Vor Biopharma?

Summary

How does Foghorn Therapeutics compare to ArriVent BioPharma?

Summary

How does Foghorn Therapeutics compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. ORIC, MLTX, VOR, AVBP, and AKTS

How does Foghorn Therapeutics compare to Oric Pharmaceuticals?

Is FHTX or ORIC more profitable?

Which has more volatility & risk, FHTX or ORIC?

Which has preferable valuation and earnings, FHTX or ORIC?

Does the media refer more to FHTX or ORIC?

Do insiders & institutionals believe in FHTX or ORIC?

Do analysts prefer FHTX or ORIC?

Summary

How does Foghorn Therapeutics compare to MoonLake Immunotherapeutics?

Which has more risk and volatility, MLTX or FHTX?

Does the media prefer MLTX or FHTX?

Do insiders and institutionals have more ownership in MLTX or FHTX?

Do analysts rate MLTX or FHTX?

Which has stronger earnings & valuation, MLTX or FHTX?

Is MLTX or FHTX more profitable?

Summary

How does Foghorn Therapeutics compare to Vor Biopharma?

Which has more volatility and risk, VOR or FHTX?

Do analysts prefer VOR or FHTX?

Do insiders and institutionals believe in VOR or FHTX?

Which has better earnings & valuation, VOR or FHTX?

Is VOR or FHTX more profitable?

Does the media refer more to VOR or FHTX?

Summary

How does Foghorn Therapeutics compare to ArriVent BioPharma?

Does the media prefer AVBP or FHTX?

Do analysts prefer AVBP or FHTX?

Do insiders and institutionals hold more shares of AVBP or FHTX?

Which has stronger valuation & earnings, AVBP or FHTX?

Is AVBP or FHTX more profitable?

Which has more volatility and risk, AVBP or FHTX?

Summary

How does Foghorn Therapeutics compare to Aktis Oncology?

Is AKTS or FHTX more profitable?

Do analysts rate AKTS or FHTX?

Do insiders & institutionals believe in AKTS or FHTX?

Does the media refer more to AKTS or FHTX?

Which has higher valuation & earnings, AKTS or FHTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools